Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mut… Read more
Quince Therapeutics, Inc. (QNCX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -9.375x
Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has a cash flow conversion efficiency ratio of -9.375x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.93 Million) by net assets ($1.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Quince Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Quince Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Quince Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quince Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rajshree Sugars & Chemicals Limited
NSE:RAJSREESUG
|
-0.078x |
|
Claren Energy Corp
PINK:CNENF
|
0.173x |
|
rYojbaba Co., Ltd. Common Shares
NASDAQ:RYOJ
|
0.000x |
|
Analyst IMS Investment Management Services Ltd
TA:ANLT
|
0.094x |
|
Intertech S.A. Inter. Technologies
AT:INTET
|
0.036x |
|
CP Capital Limited
NSE:CPCAP
|
N/A |
|
Citra Buana Prasida
JK:CBPE
|
0.008x |
|
SUNation Energy Inc.
NASDAQ:SUNE
|
0.110x |
Annual Cash Flow Conversion Efficiency for Quince Therapeutics, Inc. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Quince Therapeutics, Inc. from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $30.15 Million | $-31.90 Million | -1.058x | -392.27% |
| 2023-12-31 | $85.08 Million | $-18.29 Million | -0.215x | +50.89% |
| 2022-12-31 | $100.59 Million | $-44.04 Million | -0.438x | +17.51% |
| 2021-12-31 | $118.59 Million | $-62.93 Million | -0.531x | -79.89% |
| 2020-12-31 | $172.26 Million | $-50.82 Million | -0.295x | -2.37% |
| 2019-12-31 | $115.48 Million | $-33.28 Million | -0.288x | -75.98% |
| 2018-12-31 | $71.42 Million | $-11.70 Million | -0.164x | -133.79% |
| 2017-12-31 | $-20.28 Million | $-9.83 Million | 0.485x | -- |